Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free HBP Stock Alerts

Helix BioPharma (HBP) Competitors

Helix BioPharma logo
C$1.10 -0.07 (-5.98%)
As of 09/23/2026 03:58 PM Eastern
Compare

HBP vs. PLI, ABCN, TH, BCT, and SCYB

Should you buy Helix BioPharma stock or one of its competitors? Helix BioPharma's main competitors and comparable companies include ProMetic Life Sciences (PLI), VIVO Cannabis (ABCN), Theratechnologies (TH), BriaCell Therapeutics (BCT), and Scythian Biosciences (SCYB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Helix BioPharma compare to ProMetic Life Sciences?

ProMetic Life Sciences (TSE:PLI) and Helix BioPharma (TSE:HBP) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

ProMetic Life Sciences' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
ProMetic Life SciencesN/A N/A N/A
Helix BioPharma N/A -21.54%-279.98%

Helix BioPharma has lower revenue, but higher earnings than ProMetic Life Sciences. Helix BioPharma is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProMetic Life SciencesC$39.91M0.00-C$1.47B-C$63.06N/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A

0.0% of Helix BioPharma shares are held by institutional investors. 2.2% of Helix BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Helix BioPharma had 1 more articles in the media than ProMetic Life Sciences. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for ProMetic Life Sciences. ProMetic Life Sciences' average media sentiment score of 0.00 equaled Helix BioPharma'saverage media sentiment score.

Company Overall Sentiment
ProMetic Life Sciences Neutral
Helix BioPharma Neutral

Summary

Helix BioPharma beats ProMetic Life Sciences on 5 of the 9 factors compared between the two stocks.

How does Helix BioPharma compare to VIVO Cannabis?

Helix BioPharma (TSE:HBP) and VIVO Cannabis (CVE:ABCN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

In the previous week, Helix BioPharma had 1 more articles in the media than VIVO Cannabis. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for VIVO Cannabis. Helix BioPharma's average media sentiment score of 0.00 equaled VIVO Cannabis'average media sentiment score.

Company Overall Sentiment
Helix BioPharma Neutral
VIVO Cannabis Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A
VIVO CannabisN/AN/AN/AN/AN/A

VIVO Cannabis' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -21.54% -279.98%
VIVO Cannabis N/A N/A N/A

0.0% of Helix BioPharma shares are held by institutional investors. 2.2% of Helix BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Helix BioPharma beats VIVO Cannabis on 3 of the 5 factors compared between the two stocks.

How does Helix BioPharma compare to Theratechnologies?

Helix BioPharma (TSE:HBP) and Theratechnologies (TSE:TH) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

0.0% of Helix BioPharma shares are owned by institutional investors. Comparatively, 0.5% of Theratechnologies shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by company insiders. Comparatively, 1.2% of Theratechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Helix BioPharma has a net margin of 0.00% compared to Theratechnologies' net margin of -9.67%. Theratechnologies' return on equity of 36.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -21.54% -279.98%
Theratechnologies -9.67%36.00%5.15%

Theratechnologies has higher revenue and earnings than Helix BioPharma. Helix BioPharma is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A
TheratechnologiesC$84.38M2.44-C$1.96M-C$0.19N/A

Helix BioPharma has a beta of 0.722962, meaning that its share price is 28% less volatile than the broader market. Comparatively, Theratechnologies has a beta of 0.256166, meaning that its share price is 74% less volatile than the broader market.

In the previous week, Helix BioPharma and Helix BioPharma both had 1 articles in the media. Theratechnologies' average media sentiment score of 0.75 beat Helix BioPharma's score of 0.00 indicating that Theratechnologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Helix BioPharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Theratechnologies
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Theratechnologies beats Helix BioPharma on 7 of the 11 factors compared between the two stocks.

How does Helix BioPharma compare to BriaCell Therapeutics?

Helix BioPharma (TSE:HBP) and BriaCell Therapeutics (CVE:BCT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Helix BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A
BriaCell TherapeuticsN/AN/AN/A-C$0.38N/A

BriaCell Therapeutics' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -21.54% -279.98%
BriaCell Therapeutics N/A N/A N/A

0.0% of Helix BioPharma shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Helix BioPharma had 1 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for BriaCell Therapeutics. Helix BioPharma's average media sentiment score of 0.00 equaled BriaCell Therapeutics'average media sentiment score.

Company Overall Sentiment
Helix BioPharma Neutral
BriaCell Therapeutics Neutral

Summary

Helix BioPharma beats BriaCell Therapeutics on 5 of the 7 factors compared between the two stocks.

How does Helix BioPharma compare to Scythian Biosciences?

Scythian Biosciences (CVE:SCYB) and Helix BioPharma (TSE:HBP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

0.0% of Helix BioPharma shares are held by institutional investors. 2.2% of Helix BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Helix BioPharma had 1 more articles in the media than Scythian Biosciences. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for Scythian Biosciences. Scythian Biosciences' average media sentiment score of 0.00 equaled Helix BioPharma'saverage media sentiment score.

Company Overall Sentiment
Scythian Biosciences Neutral
Helix BioPharma Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scythian BiosciencesN/AN/AN/AN/AN/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A

Scythian Biosciences' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Scythian BiosciencesN/A N/A N/A
Helix BioPharma N/A -21.54%-279.98%

Summary

Helix BioPharma beats Scythian Biosciences on 3 of the 5 factors compared between the two stocks.

Get Helix BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for HBP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HBP vs. The Competition

Export
MetricHelix BioPharmaBiotechnology IndustryHealthcare SectorTSE Exchange
Market CapC$89.36MC$3.98BC$7.31BC$12.84B
Dividend Yield1.50%3.63%2.52%6.27%
P/E Ratio-27.5013.88274.0840.36
Price / SalesN/A1,343.77638.219.35
Price / Cash11.32113.2977.8082.29
Price / Book5.7215.4010.474.69
Net Income-C$50.55M-C$22.82MC$3.49BC$299.09M
7 Day Performance-21.43%-1.70%-0.67%0.01%
1 Month Performance-45.27%-6.17%-3.17%-2.14%
1 Year Performance-30.82%30.67%15.14%20.17%

Helix BioPharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HBP
Helix BioPharma
N/AC$1.10
-6.0%		N/A-31.3%C$89.36MN/AN/A9
PLI
ProMetic Life Sciences
N/AN/AN/AN/AC$317.06MC$39.91MN/A487
ABCN
VIVO Cannabis
N/AC$1.32
+5.6%		N/A+0.0%C$256.62MN/AN/AN/A
TH
Theratechnologies
N/AC$4.47
-4.9%		N/A-2.4%C$205.53MC$84.38MN/A103
BCT
BriaCell Therapeutics
N/AC$10.60
-3.8%		N/A+0.0%C$168.68MN/AN/A5

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:HBP) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...
Banyan Hill Publishing | Sponsoredtc pixel
Why I believe the AI market will split in Q4
Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...
The Oxford Club | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
On October 7th, your “safest” assets are at risk
Jeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...
Brownstone Research | Sponsoredtc pixel
While SpaceX Gets the Spotlight, FJET Is Building What Comes Next!
Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...
Trading Wire | Sponsoredtc pixel
The REAL Reason 2,000 Missiles Rained on Iran
Two private meetings with U.S. Congressmen and weeks of research point to a surprising explanation for the rec...
Behind the Markets | Sponsoredtc pixel
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel